Procaps Group SA
PROC
Company Profile
Business description
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Contact
9 Rue de Bitbourg
LuxembourgL-1273
LUXT: +356 79956138
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,500
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.40 | 161.30 | -1.84% |
| CAC 40 | 7,820.27 | 129.90 | -1.63% |
| DAX 40 | 21,368.62 | 363.43 | -1.67% |
| Dow JONES (US) | 44,544.66 | 337.47 | -0.75% |
| FTSE 100 | 8,575.22 | 98.74 | -1.14% |
| HKSE | 20,217.26 | 7.85 | -0.04% |
| NASDAQ | 19,627.44 | 54.31 | -0.28% |
| Nikkei 225 | 38,520.09 | 1,052.40 | -2.66% |
| NZX 50 Index | 12,810.32 | 184.69 | -1.42% |
| S&P 500 | 6,040.53 | 30.64 | -0.50% |
| S&P/ASX 200 | 8,379.40 | 152.90 | -1.79% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |